Keyphrases
Type 2 Diabetic Patients
100%
Glycaemia
100%
A1 Receptor
100%
Glucagon-like
100%
Receptor Agonist
100%
Liver Fat
100%
Fat Reduction
100%
Obese Type 2 Diabetes
100%
Hepatic Fat
100%
Hemoglobin A1c (HbA1c)
42%
Type 2 Diabetes Mellitus (T2DM)
28%
Abdominal Adipose Tissue
28%
Relative Reduction
28%
Sulfonylurea
14%
Glycated Hemoglobin
14%
High Prevalence
14%
Weight Loss
14%
Male Patients
14%
Obesity
14%
Liver
14%
Non-alcoholic Fatty Liver Disease (NAFLD)
14%
Type 2 Diabetes Mellitus Patients
14%
Dipeptidyl peptidase-4 (DPP-4)
14%
Treatment Level
14%
Metformin
14%
Liraglutide
14%
Obese Patients
14%
Mechanistic Studies
14%
Human Liver
14%
Whole-body Magnetic Resonance Imaging
14%
Proton Magnetic Resonance Spectroscopy
14%
Hepatic Steatosis
14%
1H-MRS
14%
Total Body Weight
14%
HbA1c Reduction
14%
Exenatide
14%
Liver Lipid Metabolism
14%
Dysglycemia
14%
Body Volume
14%
Lipid Reduction
14%
Obese Type 2 Diabetes Mellitus
14%
Pharmacology, Toxicology and Pharmaceutical Science
Glucagon Like Peptide 1 Receptor Agonist
100%
Hemoglobin A1c
100%
Fatty Liver
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon-Like Peptide-1
75%
Glycosylated Hemoglobin
25%
Sulfonylurea
25%
Prevalence
25%
Metformin
25%
Liraglutide
25%
Dipeptidyl Peptidase IV Inhibitor
25%
Nonalcoholic Fatty Liver
25%
Exendin 4
25%
Dysglycemia
25%
Agricultural and Biological Sciences
Agonist
100%
Glucagon-Like Peptide-1
100%
Glucagon-Like Peptide 1 Receptor
100%
Body Weight
66%
Prevalence
33%
Body Mass Index
33%
Adipose Tissue
33%
Magnetic Resonance Imaging
33%
Lipid Metabolism
33%
Sulfonylurea
33%
NMR Spectroscopy
33%
Pretreatment
33%
Liraglutide
33%
Immunology and Microbiology
Glucose Blood Level
100%
Body Weight
100%
Agonist
100%
Prevalence
50%
Non-Alcoholic Fatty Liver Disease
50%
Adipose Tissue
50%
Nuclear Magnetic Resonance Spectroscopy
50%
Lipid Metabolism
50%
Magnetic Resonance Imaging
50%